var data={"title":"Capreomycin: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Capreomycin: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5805?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=capreomycin-patient-drug-information\" class=\"drug drug_patient\">see &quot;Capreomycin: Patient drug information&quot;</a> and <a href=\"topic.htm?path=capreomycin-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Capreomycin: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5708654\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Renal impairment:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">The use of capreomycin in patients with renal insufficiency must be undertaken with great caution, and the risk of additional renal injury should be weighed against the benefits derived from therapy.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Because other parenteral antituberculosis agents (streptomycin, viomycin) also have similar and sometimes irreversible toxic effects, particularly on renal function, simultaneous administration of these agents with capreomycin is not recommended. Use with nonantituberculosis drugs (polymyxin A sulfate, colistin sulfate, amikacin, gentamicin, tobramycin, vancomycin, kanamycin, and neomycin) having nephrotoxic potential should be undertaken only with great caution.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Auditory impairment:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">The use of capreomycin in patients with preexisting auditory impairment must be undertaken with great caution, and the risk of additional cranial nerve VIII impairment should be weighed against the benefits derived from therapy.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Because other parenteral antituberculosis agents (streptomycin, viomycin) also have similar and sometimes irreversible toxic effects, particularly on cranial nerve VIII, simultaneous administration of these agents with capreomycin is not recommended. Use with nonantituberculosis drugs (polymyxin A sulfate, colistin sulfate, amikacin, gentamicin, tobramycin, vancomycin, kanamycin, and neomycin) having ototoxic potential should be undertaken only with great caution.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Pregnancy:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">The safety of the use capreomycin in pregnancy has not been determined.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Pediatric patients:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Safety and effectiveness in pediatric patients have not been established.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F145236\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Capastat Sulfate</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F145257\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antibiotic, Miscellaneous;</li>\n      <li>\n        Antitubercular Agent</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F145238\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Tuberculosis, pulmonary:</b> IM, IV: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Manufacturer's labeling: 1 g once daily (maximum: 20 mg/kg/dose) for 60 to 120 days, followed by 1 g 2 to 3 times weekly </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Alternate dosing: 15 mg/kg once daily (maximum: 1 g/dose) for 5 to 7 days per week for 2 to 4 months, followed by 15 mg/kg (maximum: 1 g/dose) 2 to 3 times weekly (MMWR 2003)  </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F145250\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=capreomycin-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Capreomycin: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;margin-left:0em;\">\n      <b>Tuberculosis, pulmonary:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Infants, Children, and Adolescents &lt;15 years and &le;40 kg (off-label use):  IM, IV: 15 to 30 mg/kg/dose (maximum: 1,000 mg/dose) once daily or twice weekly (MMWR 2003)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children and Adolescents &ge;15 years or &gt;40 kg (off-label use): IM, IV: 15 mg/kg once daily (maximum: 1,000 mg/dose) for 5 to 7 days per week for 2 to 4 months followed by 15 mg/kg (maximum: 1,000 mg/dose) 2 to 3 times weekly (MMWR 2003) </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F145239\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Use with caution because of the increased potential for preexisting renal dysfunction or impaired hearing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Manufacturer's labeling: Refer to adult dosing. Initiate at lower end of dosing range.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Alternate dosing: Adults &gt;59 years of age: 10 mg/kg once daily (maximum: 750 mg/dose) for 5 to 7 days per week for 2 to 4 months, followed by 10 mg/kg (maximum: 750 mg/dose) 2 to 3 times weekly (MMWR 2003).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F145240\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">Adults: </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <i>Manufacturer's labeling (maximum: 1 g/dose):</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">CrCl 110 mL/minute: 13.9 mg/kg every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">CrCl 100 mL/minute: 12.7 mg/kg every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">CrCl 80 mL/minute: 10.4 mg/kg every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">CrCl 60 mL/minute: 8.2 mg/kg every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">CrCl 50 mL/minute: 7 mg/kg every 24 hours <b>or</b> 14 mg/kg every 48 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">CrCl 40 mL/minute: 5.9 mg/kg every 24 hours <b>or</b> 11.7 mg/kg every 48 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">CrCl 30 mL/minute: 4.7 mg/kg every 24 hours <b>or</b> 9.5 mg/kg every 48 hours <b>or</b> 14.2 mg/kg every 72 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">CrCl 20 mL/minute: 3.6 mg/kg every 24 hours <b>or</b> 7.2 mg/kg every 48 hours <b>or</b> 10.7 mg/kg every 72 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">CrCl 10 mL/minute: 2.4 mg/kg every 24 hours <b>or</b> 4.9 mg/kg every 48 hours <b>or</b> 7.3 mg/kg every 72 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">CrCl 0 mL/minute: 1.3 mg/kg every 24 hours <b>or</b> 2.6 mg/kg every 48 hours <b>or</b> 3.9 mg/kg every 72 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">\n      <i>Alternate dosing:</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">MMWR 2003:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">CrCl &ge;30 mL/minute: No adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">CrCl &lt;30 mL/minute: 12 to 15 mg/kg (maximum: 1 g/dose) 2 to 3 days per week (<b>NOT</b> daily)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">End-stage renal disease (ESRD) on hemodialysis: 12 to 15 mg/kg (maximum: 1 g/dose) 2 to 3 days per week (<b>NOT</b> daily) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">Aronoff 2007:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">GFR &ge;10 mL/minute: 1 g every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">GFR &lt;10 mL/minute: 1 g every 48 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">End-stage renal disease (ESRD) on hemodialysis: Administer dose after hemodialysis only</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Continuous renal replacement therapy (CRRT): 5 mg/kg every 24 hours </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15682458\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F145219\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Injection, as sulfate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Capastat Sulfate: 1 g (1 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F145204\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F145223\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">IM: Administer by deep IM injection into a large muscle mass. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">IV: Administer over 60 minutes.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F145222\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">\n      <b>Tuberculosis, pulmonary:</b> Treatment of pulmonary infections caused by capreomycin-susceptible strains of <i>Mycobacterium tuberculosis</i>, in combination with other appropriate antituberculosis agents, when the primary agents (eg, isoniazid, rifampin, ethambutol, pyrazinamide) have been ineffective or cannot be used because of toxicity or the presence of resistant tubercle bacilli.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F145264\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Capastat may be confused with Cepastat</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F145211\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Frequency not always defined.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Otic: Ototoxicity (subclinical hearing loss: 11%; clinical loss: 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Genitourinary: Nephrotoxicity (36%, increased blood urea nitrogen) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">1% to 10%: Hematologic: Eosinophilia (dose-related, mild) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">&lt;1%, postmarketing, and/or case reports: Hepatic insufficiency (decreased sulfobromophthalein excretion), hypersensitivity (includes fever, maculopapular rash, urticaria), hypocalcemia, hypokalemia, hypomagnesemia, increased serum creatinine, injection site reaction (includes abscess at injection site, bleeding at injection site, induration at injection site, and pain at injection site), leukocytosis, leukopenia, nephritis (toxic), renal tubular necrosis, thrombocytopenia (rare), tinnitus, urine sedimentation abnormality, vertigo</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F145226\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to capreomycin or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F145208\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Electrolyte imbalance: Hypocalcemia, hypokalemia, and hypomagnesemia have been reported with use. Monitor electrolytes periodically during treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Nephrotoxicity: May cause nephrotoxicity, including tubular necrosis, increased BUN or serum creatinine, and abnormal urinary sediment; slight elevations in BUN and serum creatinine with urinary RBCs, WBCs, and casts have been observed with prolonged treatment. Monitor renal function at baseline and periodically during treatment. A BUN &gt;30 mg/dL or other evidence of decreasing renal function should prompt clinical evaluation and dosage adjustment or therapy discontinuation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Ototoxicity: May cause impairment of cranial nerve VIII, which may be irreversible; perform audiometric assessment and assessment of vestibular function prior to initiation and periodically during treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Allergies: Use with caution in patients who demonstrate some form of allergy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Auditory impairment:<b> [US Boxed Warning]: Use in patients with preexisting auditory impairment must be undertaken with great caution, and the risk of additional cranial nerve VIII impairment should be weighed against the benefits to be derived from therapy.</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal impairment:<b> [US Boxed Warning]: Use in patients with renal impairment must be undertaken with great caution, and the risk of additional renal injury should be weighed against the benefits to be derived from therapy.</b> Dosage reductions are recommended for known or suspected renal impairment. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Drugs with ototoxic or nephrotoxic potential: <b>[US Boxed Warning]: Use with nonantituberculous drugs (eg, polymyxin A sulfate, colistin sulfate, gentamicin, tobramycin, vancomycin, neomycin) having ototoxic or nephrotoxic potential should be undertaken only with great caution. </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Parenteral antituberculous agents: <b>[US Boxed Warning]: Because other parenteral antituberculous agents (eg, streptomycin, viomycin) also have similar and sometimes irreversible toxic effects, particularly on cranial nerve VIII and renal function, simultaneous administration of these agents with capreomycin is not recommended.</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Elderly: Use with caution.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Pediatric: <b>[US Boxed Warning]: Safety has not been established in pediatric patients.</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Pregnancy: <b>[US Boxed Warning]: Safety has not been established in pregnant women.</b></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13298954\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F145213\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9194&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Aminoglycosides: Capreomycin may enhance the neuromuscular-blocking effect of Aminoglycosides. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Colistimethate: Capreomycin may enhance the neuromuscular-blocking effect of Colistimethate. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mecamylamine: Capreomycin may enhance the neuromuscular-blocking effect of Mecamylamine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular-Blocking Agents: Capreomycin may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Polymyxin B: Capreomycin may enhance the neuromuscular-blocking effect of Polymyxin B. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F145215\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F145228\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been reported in animal reproduction studies. <b>[US Boxed Warning]: Safety has not been established in pregnant women</b>; avoid use during pregnancy because of the risk of fetal nephrotoxicity and congenital hearing loss (MMWR 2003).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20608843\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if capreomycin is excreted in breast milk. The manufacturer recommends that caution be exercised when administering capreomycin to nursing women.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F145217\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">Audiometric measurements and vestibular function at baseline and during therapy; renal function at baseline and weekly during therapy; baseline and frequent assessment of serum electrolytes (including calcium, magnesium, and potassium), liver function tests </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F145220\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:0em;display:inline\">Recommended concentration for susceptibility testing: 10 mcg/mL (MMWR 2003)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F145207\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Capreomycin is a cyclic polypeptide antimicrobial. It is administered as a mixture of capreomycin IA and capreomycin IB. The mechanism of action of capreomycin is not well understood. Mycobacterial species that have become resistant to other agents are usually still sensitive to the action of capreomycin. However, significant cross-resistance with viomycin, kanamycin, and neomycin occurs.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F145225\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Oral: Not absorbed </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: CrCl 100 to 110 mL/minute: 5 to 6 hours; CrCl 50 to 80 mL/minute: 7 to 10 hours; CrCl 20 to 40 mL/minute: 12 to 20 hours; CrCl 10 mL/minute: 29 hours; CrCl 0 mL/minute: 55 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: IM: 1 to 2 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (52% unchanged within 12 hours)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323040\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Capastat Sulfate Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 g (1): $258.54</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F145229\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Capacin (KR);</li>\n      <li>Capastat (AT, AU, CZ, ES, GR, IE, NZ, PL, RU);</li>\n      <li>Kapocin (ET, IN, TH)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American Thoracic Society; CDC; Infectious Diseases Society of America. Treatment of tuberculosis [published correction appears in <i>MMWR Recomm Rep</i>. 2005;53(51):1203]. <i>MMWR Recomm Rep</i>. 2003;52(RR-11):1-77. <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5211a1.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5211a1.htm</a>.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/capreomycin-drug-information/abstract-text/12836625/pubmed\" target=\"_blank\" id=\"12836625\">12836625</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al, <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed. Philadelphia, PA: American College of Physicians; 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Capastat sulfate (capreomycin for injection) [prescribing information]. Lake Forest, IL: Akorn Inc; September 2009.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC), &quot;Treatment of Tuberculosis,&quot; <i>MMWR Recomm Rep</i>, 2003, 52(RR-11):1-77. Available at <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5211a1.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5211a1.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/capreomycin-drug-information/abstract-text/12836625[/pubmed\" target=\"_blank\" id=\"12836625[\">12836625[</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Davidson PT and Le HQ, &ldquo;Drug Treatment of Tuberculosis - 1992,&rdquo; <i>Drugs</i>, 1992, 43(5):651-73.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/capreomycin-drug-information/abstract-text/1379145/pubmed\" target=\"_blank\" id=\"1379145\">1379145</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    DHHS Panel on Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Department of Health and Human Services. November 2013. Available at <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/oi_guidelines_pediatrics.pdf\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/oi_guidelines_pediatrics.pdf</a>.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    DHHS Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. October 2014. Available at <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf</a>. Accessed November 12, 2014</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &ldquo;Drugs for Tuberculosis,&rdquo; <i>Med Lett Drugs Ther</i>, 1993, 35(908):99-101.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/capreomycin-drug-information/abstract-text/8412982/pubmed\" target=\"_blank\" id=\"8412982\">8412982</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Iseman MD, &ldquo;Treatment of Multidrug-Resistant Tuberculosis,&rdquo; <i>N Engl J Med</i>, 1993, 329(11):784-91.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/capreomycin-drug-information/abstract-text/8350889/pubmed\" target=\"_blank\" id=\"8350889\">8350889</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lehmann CR, Garrett LE, Winn RE, et al, &ldquo;Capreomycin Kinetics in Renal Impairment and Clearance by Hemodialysis,&rdquo; <i>Am Rev Respir Dis</i>, 1988, 138(5):1312-3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/capreomycin-drug-information/abstract-text/2462388/pubmed\" target=\"_blank\" id=\"2462388\">2462388</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nahid P, Dorman SE, Alipanah N, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: treatment of drug-susceptible tuberculosis. <i>Clin Infect Dis</i>. 2016;63(7):e147-195.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/capreomycin-drug-information/abstract-text/27516382/pubmed\" target=\"_blank\" id=\"27516382\">27516382</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9194 Version 103.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5708654\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F145236\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F145257\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F145238\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F145250\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F145239\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F145240\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F15682458\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F145219\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F145204\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F145223\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F145222\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F145264\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F145211\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F145226\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F145208\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13298954\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F145213\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F145215\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F145228\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F20608843\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F145217\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F145220\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F145207\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F145225\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323040\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F145229\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9194|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=capreomycin-patient-drug-information\" class=\"drug drug_patient\">Capreomycin: Patient drug information</a></li><li><a href=\"topic.htm?path=capreomycin-pediatric-drug-information\" class=\"drug drug_pediatric\">Capreomycin: Pediatric drug information</a></li></ul></div></div>","javascript":null}